Gritstone Bio Inc 's Cash & cash equivalent grew by 20.32 % in the Q2 2024 sequentially, while Current Liabilities decreased, this led to improvement in Gritstone Bio Inc 's Quick Ratio to 2.33, Quick Ratio remained below Gritstone Bio Inc average.

Within Biotechnology & Pharmaceuticals industry 113 other companies have achieved higher Quick Ratio than Gritstone Bio Inc in second quarter 2024. While Quick Ratio total ranking has improved so far during the Q2 2024 to 1086, from total ranking in the first quarter 2024 at 1139.

Explain Quick Ratio?
How much Cash & cash equivalents GRTS�s has?
What are GRTS�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

GRTS Quick Ratio	(Jun 30 2024) Q2	(Mar 31 2024) Q1	(Dec 31 2023) Q4	(Sep 30 2023) Q3	(Jun 30 2023) Q2
Y / Y Current Liabilities Change	8.1 %	4.86 %	-21.44 %	-27.64 %	-31.73 %
Y / Y Cash & cash equivalent Change	-51.36 %	-68.24 %	-53.88 %	-39.96 %	-20.81 %
Quick Ratio MRQ	2.33	1.79	2.9	3.59	5.18
GRTS's Total Ranking	# 1086	# 1139	# 832	# 901	# 598
Seq. Current Liabilities Change	-7.61 %	-5.37 %	16.92 %	5.75 %	-10.38 %
Seq. Cash & cash equivalent Change	20.32 %	-41.59 %	-5.57 %	-26.7 %	-21.45 %

Quick Ratio second quarter 2024 Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 114
Healthcare Sector	# 502
Overall Market	# 1086

Quick Ratio Statistics
High	Average	Low
15.67	5.92	1.79
(Dec 31 2018)		(Mar 31 2024)

Financial Statements
Gritstone Bio Inc 's Current Liabilities	$ 24 Millions	Visit GRTS's Balance sheet
Gritstone Bio Inc 's Cash & cash equivalent	$ 56 Millions	Visit GRTS's Balance sheet
Source of GRTS's Sales		Visit GRTS's Sales by Geography

Cumulative Gritstone Bio Inc 's Quick Ratio

GRTS's Quick Ratio for the trailling 12 Months

GRTS Quick Ratio	(Jun 30 2024) 12 Months	(Mar 31 2024) 12 Months	(Dec 31 2023) 12 Months	(Sep 30 2023) 12 Months	(Jun 30 2023) 12 Months
Y / Y Current Liabilities TTM Growth	-11.77 %	-20.51 %	-27.01 %	-24.34 %	-20.21 %
Y / Y Cash & cash equivalent TTM Growth	-53.63 %	-46.18 %	-32.61 %	-21.58 %	-20.34 %
Quick Ratio TTM	2.64	3.28	4.34	4.92	5.02
Total Ranking TTM	# 3389	# 3207	# 3160	# 3248	# 3450
Seq. Current Liabilities TTM Growth	1.81 %	1.23 %	-7.11 %	-7.84 %	-8.27 %
Seq. Cash & cash equivalent TTM Growth	-18.15 %	-23.49 %	-17.94 %	-9.77 %	-5 %

Quick ratio ranking by company, industry and sector >> Back to GRTS Financial Strength Comparisons >> Go to Compare GRTS Quick Ratio to its Competitors

News about Gritstone Bio Inc Quick Ratio

Gritstone Bio Announces Inducement Grants as it Envisions Development of Powerful Vaccines

In a recent announcement, Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company committed to revolutionizing vaccine development, revealed the grant of nonqualified stock options to a new employee. These stock options, totaling 6,850 shares of common stock, carry an exercise price of $0.75, mirroring the closing price of Gritstone s common stock on June 7, 2024. The inducement grant was made in accordance with Nasdaq Listing Rule 5635(c)(4) and aims to attract skilled individuals as Gritstone pursues its mission to create the world s most potent vaccines.
The Power of Gritstone:
Based in Emeryville, California, Gritstone bio is focused on utilizing next-generation immunotherapies to develop vaccines with unparalleled efficacy. Employing its proprietary technology platform, EDGE™ (Epitope-Specific Immunotherapy), the company aims to address significant unmet medical needs in the field of infectious diseases and cancer.

On the trailing twelve months basis Due to decrease in Current Liabilities in the Q2 2024 to $23.90 millions, cumulative Quick Ratio decreased to 2.64 below the average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 151 other companies have achieved higher Quick Ratio than Gritstone Bio Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2024 from 3207 to 3389.

Explain Quick Ratio?
How much Cash & cash equivalents GRTS�s has?
What are GRTS�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Biotechnology & Pharmaceuticals Industry	# 152
Healthcare Sector	# 931
Within the Market	# 3389

trailing twelve months Quick Ratio Statistics
High	Average	Low
8.92	5.67	2.64
(Jun 30 2019)		(Jun 30 2024)

Companies with similar Quick Ratio in the quarter ending Jun 30 2024, within Biotechnology & Pharmaceuticals Industry	Quick Ratio	Jun 30 2024 MRQ Cash & cash equivalent	Jun 30 2024 MRQ Current Liabilities
Surrozen Inc	6.31	$ 37.765 Millions	$ 5.983 Millions
Monte Rosa Therapeutics Inc	6.19	$ 262.205 Millions	$ 42.348 Millions
Inhibrx Biosciences Inc	6.15	$ 226.860 Millions	$ 36.881 Millions
X4 Pharmaceuticals Inc	6.09	$ 168.754 Millions	$ 27.730 Millions
Genenta Science S p a	6.03	$ 14.179 Millions	$ 2.351 Millions
Tenaya Therapeutics Inc	5.94	$ 99.303 Millions	$ 16.712 Millions
Arcellx Inc	5.85	$ 516.688 Millions	$ 88.290 Millions
Beam Therapeutics Inc	5.69	$ 1,008.165 Millions	$ 177.333 Millions
Metagenomi Therapeutics Inc	5.68	$ 299.921 Millions	$ 52.810 Millions
Fennec Pharmaceuticals Inc	5.56	$ 43.054 Millions	$ 7.749 Millions
Recursion Pharmaceuticals Inc	5.51	$ 474.341 Millions	$ 86.083 Millions
Humacyte Inc	5.27	$ 93.563 Millions	$ 17.757 Millions
Ginkgo Bioworks Holdings Inc	5.21	$ 730.367 Millions	$ 140.147 Millions
Dyadic International Inc	5.18	$ 10.098 Millions	$ 1.949 Millions
Cardiff Oncology Inc	5.10	$ 60.319 Millions	$ 11.820 Millions
Taysha Gene Therapies Inc	5.05	$ 172.743 Millions	$ 34.176 Millions
Quince Therapeutics Inc	5.00	$ 51.555 Millions	$ 10.321 Millions
Hillevax Inc	4.98	$ 245.040 Millions	$ 49.165 Millions
Sana Biotechnology Inc	4.96	$ 251.643 Millions	$ 50.689 Millions
Sab Biotherapeutics Inc	4.94	$ 37.326 Millions	$ 7.552 Millions
Repligen Corp	4.94	$ 809.146 Millions	$ 163.747 Millions
Immunocore Holdings Plc	4.68	$ 859.597 Millions	$ 183.709 Millions
Compugen Ltd	4.55	$ 92.004 Millions	$ 20.228 Millions
Pharmacyte Biotech Inc	4.37	$ 32.635 Millions	$ 7.473 Millions
Cardiol Therapeutics inc	4.36	$ 23.424 Millions	$ 5.370 Millions
Biomx Inc	4.33	$ 31.611 Millions	$ 7.305 Millions
Artiva Biotherapeutics Inc	4.30	$ 46.556 Millions	$ 10.827 Millions
Cidara Therapeutics Inc	4.15	$ 164.369 Millions	$ 39.643 Millions
Invivyd Inc	4.11	$ 147.881 Millions	$ 36.023 Millions
Aligos Therapeutics Inc	4.01	$ 94.536 Millions	$ 23.564 Millions

Date modified: 2026-09-18T13:11:05+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.